-+ 0.00%
-+ 0.00%
-+ 0.00%

InflaRx Reviews Phase 3 Data for Vilobelimab in Pyoderma Gangrenosum After Early Trial Termination

Reuters·12/30/2025 12:30:20

Please log in to view news